Vancouver-based Aspect Biosystems has raised an impressive USD $115 million in Series B funding, signaling a major step forward in the development of bioprinted tissue therapeutics.
The financing round was led by Dimension, a life sciences and technology-focused investment firm, with participation from new and returning investors including Novo Nordisk, Radical Ventures, InBC, and others.
Building on partnerships with the governments of Canada and British Columbia and a diabetes and obesity collaboration with Novo Nordisk, the funds will accelerate Aspect’s work on bioprinted tissue therapeutics. The company’s mission centers on delivering a groundbreaking class of cellular medicines and functional cures for serious metabolic and endocrine diseases.
Aspect Biosystems is a member of the BC Tech Association.
BC Tech is the largest member-led technology non-profit in British Columbia, and we’re dedicated to turning startups and scaleups into the anchor companies of tomorrow. Our work supports members to grow and diversify their talent pool, acquire new customers, access capital and accelerate their scaleup journey. Technology is a key industry for BC’s future and builds resiliency in every industry. Today, every company is a tech company. Join now.
The investment will also expand Aspect’s advanced tissue therapeutic platform, integrating AI-powered bioprinting, computational design, therapeutic cells, and innovative biomaterials.
“We are thrilled to partner with this mission-aligned investor syndicate,” said Tamer Mohamed, Founder and CEO of Aspect Biosystems. “Their support enables us to pursue disease-modifying treatments and transform patient outcomes.”
As part of the deal, Nan Li, Founder and Managing Partner at Dimension, joins Aspect’s Board of Directors. Li praised Aspect as a leader in multidisciplinary biotech innovation, highlighting its integration of tissue engineering, cell therapy, biomaterials, and robotics as key to advancing regenerative medicine.
Aspect’s advancements mark a transformative era in biotechnology, with this funding solidifying its role at the forefront of regenerative medicine.
Leave a Reply